drugset / Trial / NCT05102149

Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus

NCT05102149

Phase 3 Unknown 672 enrolled PegBio Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multicenter, randomized, double-blind, parallel, Vildagliptin and Placebo-Controlled study to evaluate the efficacy and safety of oral administration of 100 mg of PB-201 in the morning and evening in treatmentnaive patients with type 2 diabetes mellitus.

Timeline

Start
2021-09-30
Primary completion
2023-11
Completion
2025-04

Drugs

EvaluationDrugModalityDoseRoute
Subject PB-201 Unknown 100 mg Oral
Comparator Vildagliptin Other / unclassified 50 mg Oral